To investigate whether ureteroscopy (URS) before radical nephroureterectomy (RNU) for upper tract urothelial carcinomas (UTUCs) has an impact on oncological outcomes.
Introduction
Upper tract urothelial carcinoma (UTUC) is an uncommon malignant disease, accounting for 5-10% of all UCs [1] [2] [3] , with an estimated annual incidence in Western countries of approximately two cases per 100 000 inhabitants. About 60% of patients with UTUC have invasive disease at diagnosis [4, 5] . The 'gold-standard' treatment for UTUC is radical nephroureterectomy (RNU) with bladder cuff removal [1] . Recurrence in the bladder after standard rapid development of endoscopic techniques, URS has become increasingly accessible and can be used to explore the entire upper urinary tract [11] . Furthermore, URS is a practical and powerful tool to diagnose and treat patients with UTUC. Such ureteroscopic biopsies can determine tumour grade in 90% of patients, with low false-negative rates [12] . URS can prove to be invaluable in cases of suspected UTUC; especially when the diagnosis is equivocal or if nephron-sparing surgery is considered. However, the URS procedure and relevant operation prior to RNU may increase the risk of renal tumours and UC implantation, which may theoretically occur due to ureteroscope manipulation or tumour dissemination due to irrigation back-flow; anecdotal reports suggest tumour seeding as a consequence of URS [13, 14] .
In the present study, we aimed to evaluate whether URS before RNU for UTUC has an impact on oncological outcomes.
Patients and methods

Search strategy
A systematic literature search was performed using PubMed, Web of Science, and EMBASE. All the search articles were written in English. The latest search was updated in September 2017. The main keywords used for the search were 'ureteroscopy', 'nephroureterectomy', 'prognosis' or 'survival' or 'oncological outcome', and 'upper tract urothelial neoplasms' or 'upper tract urothelial cancer' or 'transitional cell carcinoma of the upper urinary tract'. The detailed search terms and strategies are shown in the Text S1 (online). Additionally, we manually screened the references from the relevant literature, including all of the identified studies, reviews, and editorials. Two independent investigators (R.-Q.G. and P.H.) assessed the titles and abstracts of published studies, and divergences were settled by consensus.
Inclusion and exclusion criteria of trials
Studies were included if they met all of the following criteria: (i) studies analysing the relationship between URS and UTUC prognosis after RNU; (ii) studies that clearly described outcome assessment by reporting overall survival (OS), cancer-special survival (CSS), recurrence-free survival (RFS), metastasis-free survival (MFS), or intravesical recurrence-free survival (IRFS); (iii) survival outcome was further explored considering the hazard ratio (HR) and corresponding 95% CI or sufficient information to achieve an estimated HR and 95% CI by using the methods reported by Tierney et al. [15] ; (iv) retrospective or prospective study design; and (v) median follow-up of >12 months. The excluded studies met one of the following criteria: (i) the article was a review or metaanalysis; (ii) no available data could be extracted from the previously published studies; (iii) the article dealt with recurrent UTUC, metastatic carcinoma, previous or concurrent invasive bladder tumours, or neoadjuvant chemotherapy; and (iv) (potentially) overlapping study populations were reported for the same outcome.
Data extraction
The data were extracted from full length articles by two reviewers (R.-Q.G. and P.H.) independently using a standardised-items form. The extracted information included name of the author; year of publication; study region; type of study; sample size; median follow-up time; median age; number of patients receiving URS; tumour location and grade; tumour pathological stage; previous bladder tumour history; outcomes, including CSS, OS, RFS, MFS, or IRFS. Divergences were settled through consensus.
Quality assessment
The quality of the selected studies was assessed independently by two reviewers (R.-Q.G. and P.H.) using the NewcastleOttawa scale, which is recommended for the assessment of non-randomised studies [16] . This scale assesses risk in three domains: patient selection, comparability of the URS before RNU (URS+) and URS not performed before RNU (URSÀ) groups, and assessment of outcome. Any divergence was settled by discussion or through arbitration by a third reviewer if no agreement could be reached.
Data analysis and synthesis
We used log HR and the variance as the summary outcome measure from all trials in the meta-analysis. For each study, the HR with the 95% CI of the survival rate was derived to evaluate the impact of URS on the survival of patients with UTUC. When there was no evident heterogeneity existing among studies (I 2 >50% and P < 0.1 suggested obvious heterogeneity) [17] , we used the fixed-effects model (Mantel-Haenszel method) to pool the results. Otherwise, the random-effects model (DerSimonian and Laird method) was applied, which provided more conservative estimates than the fixed-effects model when heterogeneity was present [18] . Potential sources of heterogeneity, if significant, were explored using subgroup analysis and meta-regression analysis.
The publication bias of selected studies was detected using funnel plots, and the Egger's test was used to assess publication bias statistically [19] . Review manager version 5.3 (Cochrane Collaboration, Oxford, UK) was used for data analysis. A P < 0.05 was considered statistically significant. search. Using literature manager software (Endnote), 258 duplicated papers were excluded. After carefully screening titles and abstracts of identified records, 265 were excluded: 103 were not relevant, 101 were case series/case reports, and 61 were reviews/letters/comments. In all, 29 were reviewed in depth, and a full examination of the text was performed. In all, 20 studies were excluded because of insufficient outcomes, and one was excluded due to potentially overlapping study populations. Finally, eight studies were included in the present meta-analysis [20] [21] [22] [23] [24] [25] [26] [27] . Table 1 summarises the characteristics of the included studies [20] [21] [22] [23] [24] [25] [26] [27] . The eight studies contained 3975 patients with UTUC, including 1070 patients who received URS before RNU (URS+ group). These patients with UTUC came from different countries or regions (USA, Japan, Austria, Canada, Germany, Italy, Chinese Taipei, France, Korea, and China) with a duration of follow-up of >12 months. Of the eight eligible studies, five studies [21] [22] [23] [24] 27] containing 2585 patients were conducted to investigate the impact of URS on the CSS of patients with UTUC after RNU, two studies [20, 27] containing 297 patients investigated OS, two studies [22, 24] containing 1780 patients investigated RFS, four studies [20, 23, 24, 27] containing 1205 patients investigated MRS, and five studies [21, 23, [25] [26] [27] containing 2099 patients investigated IRFS. Assessment of quality scores by the Newcastle-Ottawa scale showed that the scores of selected studies ranged from 7 to 9, which were considered adequate for the following meta-analysis ( Table 1 ). The summary of included studies (treatment, including surgery and neoadjuvant/adjuvant therapy) is shown in Table 2 .
Meta-analysis results
CSS
Of the five studies that referred to CSS, there was no heterogeneity (I 2 = 2%, chi-squared = 4.08, P = 0.40); thus, the fixed-effects model was used to calculate the pooled HR and corresponding 95% CI. As shown in Figure 2A , the combined HR of these studies revealed that URS before RNU was associated with better CSS in patients with UTUC (HR 0.76, 95% CI 0.59-0.99; P = 0.04). To explore the source of better CSS in the URS+ group, we compared the differences in tumour stage and tumour grade between the groups, thereby demonstrating the features between the groups using Table 3 ). The results showed that there were remarkable significant differences in tumour stage between the URS+ and URSÀ groups (P < 0.001). However, there was no significant difference in tumour grade between the two groups (P = 0.104). When excluding the studies containing patients receiving adjuvant therapy, there was no significant difference between the two groups (HR 0.83, 95% CI 0.58-1.17; P = 0.28) without heterogeneity (I 2 = 17%, chi-squared = 3.63, P = 0.30) (Fig. 2B) .
OS
Data for OS were reported in only two studies, and there was no significant difference in study heterogeneity (I 2 = 0%, chisquared = 0.11, P = 0.51); thus, the fixed-effects model was used to pool the results. The data showed that no significant difference between the URS+ and the URSÀ groups (HR 0.76, 95% CI 0.48-1.21; P = 0.24) (Fig. 2C) .
RFS
There was no significant heterogeneity in the two studies that focused on RFS (I 2 = 0%, chi-squared = 0.96, P = 0.33); thus, the fixed-effects model was used to pool the results. The pooled HR for RFS was 0.89 (95% CI 0.69-1.14; P = 0.37), indicating that URS before RNU was not associated with poor RFS in patients with UTUC (Fig. 2D) .
MFS
There were five studies that assessed MFS of URS+ vs URSÀ before RNU. The results showed that the risk of metastasis for patients with UTUC with URS was not higher than those without URS (HR 1.06, 95% CI 0.82-1.36; P = 0.66) and there was no significant heterogeneity (I 2 = 0%, chi-squared = 0.53, P = 0.66) (Fig. 2E) .
IRFS
Of the five studies that referred to IRFS, irrespective of previous bladder tumour history, there was no inter-study heterogeneity (I 2 = 37%, chi-squared = 6.34, P = 0.18); thus, the fixed-effects model was used to pool the results. The combined HRs of these studies revealed that URS before RNU (URS+) was associated with poorer IRFS in patients with UTUC (HR 1.51, 95% CI 1.29 -1.77; P < 0.001) (Fig. 3A) . When excluding previous bladder tumour history, patients in the URS+ group were still at higher risk of intravesical recurrence compared with those in the URSÀ group (HR 1.81, 95% CI 1.53-2.13; P < 0.001), with no heterogeneity amongst the studies (I 2 = 0%, chi-squared = 1.29, P = 0.73) (Fig. 3B) . We further confined included studies to those with bladder cuff management, the risk of intravesical recurrence for patients UTUC with URS was higher than for those without URS (HR 1.61, 95% CI 1.30-1.99; P < 0.001), with no heterogeneity (I 2 = 0%, chi-squared = 0.99, P = 0.61) (Fig. 3C ).
Publication bias
Publication bias was detected using a funnel plot of the metaanalysis result. The basic symmetry of the funnel plots suggested that there was no obvious publication bias in this meta-analysis (Fig. 4) . The Egger's test for CSS, OS, RFS, MFS, and IRFS did not show any evidence of publication bias.
Discussion
The relationship between URS and oncological outcomes in patients with UTUC has attracted extensive attention and has been widely debated; however, the reports remain controversial, and there has yet to be a consensus on whether URS before RNU increases the risk of disease progression or death from disease. Thus, we reviewed the published studies to evaluate the impact of URS before RNU on UTUC survival and conducted a standard meta-analysis to assess whether URS before RNU showed a tendency towards a poor prognosis for patients with UTUC.
In the present study, based on the inclusion and quality assessment criteria, eight studies were eligible, and the HRs of cumulative survival rates were summarised quantitatively subdivided the URS group into those undergoing therapeutic laser ablation and those undergoing tissue biopsy. Although the time delay between the ablation group and the biopsy group differed significantly (40.1 month vs 1 month), no significant difference was found in the postoperative disease status between patients undergoing RNU after ablation and those who received RNU after endoscopic biopsy or those who did not undergo URS before RNU. Our present results indicated that URS did not have a significant negative impact on OS, RFS, or MFS for patients with UTUC who finally underwent radical surgery. Interestingly, URS was significantly associated with better CSS (HR 0.76, 95% CI 0.59-0.99; P = 0.04). For this result, we contributed it to selection bias ( Table 2) . It was more likely that patients with advanced disease (>pT2) had apparent imaging findings, such as a solid mass on CT or a filling defect on contrast imaging and positive urinary cytology. In such cases, the surgeon would omit diagnostic URS and proceed to radical surgery, which may have resulted in worse survival in the URSÀ group. Aggressive disease may be more likely to be diagnosed without diagnostic URS, even when it is ultimately categorised as the same pathological stage. A study by Ishikawa et al. [21] also showed that patients with UTUC without prior URS for ≥pT3 disease were at higher risk of cancer-specific mortality compared with those with URS before RNU and that, on multivariate analysis pathological stage and node status were independent prognostic factors. When confined to patients without adjuvant therapy, URS before RNU was not associated with poor CSS, which indicated that adjuvant therapy could be a confounder. Thus, we believe that URS does not adversely affect oncological outcomes as assessed by overall recurrence, metastasis, and mortality.
Regarding intravesical recurrence, our analysis demonstrated that URS was associated with poorer IRFS (HR = 1.51, 95% CI: 1.29-1.77, P < 0.001) irrespective of prior bladder tumor history (HR = 1.81, 95% CI: 1.53-2.13, P < 0.001), which is a well-known prognostic factor of intravesical recurrence [29] [30] [31] [32] , and was even confined to bladder cuff resection (HR = 1.61, 95% CI: 1.30-1.99, P < 0.001). Similar results were also reported by Marchioni et al. [33] . Several theories have been suggested to explain intravesical recurrence after RNU, including intraluminal tumour seeding, intraepithelial cancer migration, and urinary tract cancerisation [23, 34] . Patients with distal ureteric tumours, a site that is associated with increased risk of intravesical recurrence, were more likely to undergo URS before RNU [21, 27] . These theories have also been applied to intravesical recurrence following prior URS. We suggest that care should be taken in patients with UTUC at risk of intravesical recurrence. Intravesical chemotherapy after URS may prevent intravesical recurrence and prevent the need for additional surgical interventions. Randomised control trials are needed to assess the effects of post-URS intravesical chemotherapy on intravesical recurrence.
To the best of our knowledge, this is the first study to evaluate the relevance between prior URS and survival for patients with UTUC using comprehensive and standard meta-analysis following the guideline proposed by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA; Text S2); however, limitations should be acknowledged when drawing conclusions. First, this research was based on retrospective studies. Although all of the eight eligible studies, involving 3998 patients, were of high quality (>6 stars) according to the modified Newcastle-Ottawa scale, intrinsic bias still existed, which might have rendered the results less reliable. Second, we failed to distinguish a relationship between different locations of tumours and survival due to lack of information. Pelvis and ureteric TCCs are not the same disease in terms of invasion and prognosis [35, 36] . Third, there were only two studies investigating RFS and MFS of UTUC even after a comprehensive literature search, which might have inevitably increased the risk of random error; therefore, more large prospective studies are needed to further confirm our present findings. Fourth, there was considerable confounding by indication of URS within the representative series. Only 26.9% of patients underwent URS before RNU and those patients who did not undergo URS were more likely to have a high-volume tumour noted on axial imaging, which might influence the results of survival analysis. Furthermore, without preoperative grade assessment by URS or clinical staging by axial imaging, it is difficult to ascertain suitability for neoadjuvant chemotherapy, which does not appear to have occurred in the eight studies but still needs to be evaluated in future studies. Finally, despite the well-recognised advantages of meta-analysis, the results are affected by the quality of the included studies and the reporting bias that papers with null or nonsignificant results that are more difficult to publish than those with significant results might be unavoidable [37] . 
Conclusions
In conclusion, our present meta-analysis of current evidence suggests that URS before RNU does not have a negative impact on CSS, OS, RFS, or MFS in patients with UTUC. However, patients are at higher risk of intravesical recurrence after RNU when they have undergone prior URS. Further studies are needed to assess the effects of post-URS intravesical chemotherapy on intravesical recurrence.
